# Asit Parikh

> Asit Parikh is a physician-scientist turned biotech chief executive who runs MOMA Therapeutics, a Cambridge, Massachusetts company built around the idea of systematically drugging molecular machines - the highly dynamic, shape-shifting proteins that most drug hunters avoid. An MD-PhD trained at Vanderbilt with clinical roots in gastroenterology, he spent two decades at Millennium and Takeda, where he helped steer the inflammatory bowel disease drug vedolizumab (Entyvio) from research to global blockbuster, before taking the CEO seat at MOMA in 2021. He has since raised a $150 million Series B and signed a roughly $2 billion partnership with Roche to push precision cancer medicines toward the clinic.

- **Role:** President and Chief Executive Officer at MOMA Therapeutics
- **Organizations:** MOMA Therapeutics, Takeda Pharmaceuticals, Millennium Pharmaceuticals, Phathom Pharmaceuticals, Ambys Medicines, Newton-Wellesley Hospital, Vanderbilt University School of Medicine
- **Nationality:** American
- **Education:** B.S., Northwestern University, M.D. and Ph.D. in biochemistry (Medical Scientist Training Program), Vanderbilt University, Internal medicine residency, University of Pennsylvania, Gastroenterology fellowship, Massachusetts General Hospital, Postdoctoral cancer biology research, Massachusetts Institute of Technology (MIT)
- **Known for:** Led the clinical development of vedolizumab (Entyvio) through Millennium and Takeda into a global blockbuster for ulcerative colitis and Crohn's disease., Oversaw global regulatory approvals at Takeda for Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel and Motegrity., Identified and executed over 25 business development deals at Takeda, including licensing, M&A and company creation.

## Career timeline

- **2000s** — Joins Millennium Pharmaceuticals' clinical research division, holding leadership roles in inflammation and oncology drug development.
- **2012** — Becomes Senior Vice President and Head of Takeda's Gastroenterology Therapeutic Area Unit.
- **2012-2020** — Leads Takeda GI to global approvals including Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel and Motegrity; executes 25+ business development deals.
- **2021** — Appointed President and CEO of MOMA Therapeutics, effective April 5, 2021.
- **2022** — Closes a $150 million Series B financing to advance MOMA's precision oncology pipeline.
- **2024** — Announces a collaboration with Roche worth roughly $2 billion in potential value to develop precision cancer drugs.
- **2025** — Signals MOMA is preparing for an eventual IPO but is 'not in a rush.'

## Achievements

- Led the clinical development of vedolizumab (Entyvio) through Millennium and Takeda into a global blockbuster for ulcerative colitis and Crohn's disease.
- Oversaw global regulatory approvals at Takeda for Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel and Motegrity.
- Identified and executed over 25 business development deals at Takeda, including licensing, M&A and company creation.
- Raised a $150 million Series B for MOMA Therapeutics in May 2022, during a historic biotech market downturn.
- Signed a precision-oncology partnership with Roche valued at roughly $2 billion in potential milestones.

## Latest updates

- **2025-01** — At biotech's biggest annual event, Parikh said MOMA is preparing for a possible IPO but is 'not in a rush.'
- **2024-01** — MOMA announced a precision-oncology collaboration with Roche worth roughly $2 billion in potential value.

## Links

- Website: https://momatx.com
- LinkedIn: http://www.linkedin.com/in/asit-parikh-3463b09b

---

Profile page: https://yespress.io/asit-parikh
Published by YesPress — https://yespress.io
Last updated: 2026-06-14